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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate retention, and quality of initiation and maintenance of HIV/AIDS care, in HIV treatment care models that decentralise
from hospitals to more basic levels of care.
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B A C K G R O U N D
Description of the condition
The spread and volume of HIV care and treatment services has
increased markedly in low and middle-income countries (LMIC).
As of mid-2011, over 6million people were receiving antiretroviral
therapy (ART) in LMIC. In spite of progress to date, the global
coverage for ART is still below50% (UNAIDS 2011). The current
rate of enrolment of patients on ART is insufficient to reach the
global goal.
An effective service needs HIV testing and counselling services to
be linked to HIV care and treatment; requires ART initiation as
early as recommendedbyWHO; and a service that retains patients.
This will help decrease AIDS-related mortality, reduce costs and
maximize efficiency gains, and avert new infections (Ford 2011).
Yet there are a number of constraints at all of these steps; for
example, recent systematic reviews have indicated that, for those
who do initiate ART, retention in care is a major challenge, with
around 30%of patients estimated to be lost to follow-up within 24
months of initiating ART (Fox 2010). Access to care appears to be
an important driver of poor retention, with transport costs, time
spent travelling to health facilities, and time waiting for services
at health facilities all cited as reasons for defaulting (Kagee 2011;
Miller 2010; Ware 2009).
Description of the intervention
In order to increase access to care -- both to allow more people to
be treated, and for those that are in care, to improve retention -
- a number of countries have introduced two important, linked
adaptations to the traditional, “Western-based” model of care pro-
vision: first, the “task shifting” of treatment from more highly
trained specialists and medical practitioners to nurses; secondly,
the decentralisation of ART care delivery from hospitals to more
peripheral health facilities.
Task shifting is the process whereby specific tasks are transferred
to different cadres of health workers who have had less training
and have fewer qualifications. Task shifting aims to make efficient
use of existing health care workers in order to ease delays in service
delivery (WHO 2008). Task shifting may also include the delega-
tion of clearly-outlined duties to various levels of health workers
who receive specific, skills-based training. Task-shifting should re-
sult in an equivalent standard of care to that provided by higher
cadres of health workers. There are trials and systematic reviews
and reports that nurses can provide care that is at least as good as
that provided by physicians (Laurant 2004; Sanne 2010).
Decentralisation of care is key for efficient service delivery, in-
cluding increasing access to care for large numbers of patients not
yet in care, and facilitating treatment closer to the homes of pa-
tients, thereby improving convenience and reducing travel costs.
The overall aim is to improve retention in care, which is a critical
outcome for successful and sustained HIV/ADS treatment. This
review primarily interrogates the value of decentralisation of care,
and the related programmatic indicator of success, retention in
care. Task shifting is being addressed by a separate Cochrane re-
view (Araoyinbo 2008).
How the intervention might work
The benefits of decentralisation include increased access to care,
which, in turn, may improve health outcomes: it may increase the
individual patient attention by nurses and counsellors, as there
may be lower staff to patient ratios; and the point of care may
be closer to the community, and the increased access may reduce
defaulting and treatment failure (Fatti 2010).
On the other hand, there is legitimate concern that the provision
of care at lower levels of the health service may result in decreased
quality of care and poorer clinical outcomes (Decroo 2009). Given
these uncertainties, the extent to which HIV/AIDS treatment is
available via decentralised services varies considerably between and
within countries. There is a need for clarity around the risks and
benefits of decentralising ART service in order to inform future
operational guidance.
One of the problems in cross-national comparisons of HIV care
is in terminology. First, with terminology of health services, and
secondly with models of decentralisation. For health services, the
problem is that “community,” “health post,” “health centre” and
“hospital services” vary in meaning and in what they represent
between countries. For example, a health centre in Tanzania has
paramedical staff, and is equivalent to a district hospital in Thai-
land.
In this review, we define each “tier” in the health system by the
staffing configuration they have (Table 1). Thus, for community,
the care is provided by someone with only a few months training;
for a health centre, this is led by a paramedic or nurse; for a hos-
pital, it is led by a doctor; and for an advanced hospital, there are
specialist doctors present. In the table we also define community
in three categories: family member, village volunteer, or a primary
health care clinic with a nurse aide or community health worker.
At community care level, systems may thus be established to de-
liver treatment at household level. This framework is to help de-
scribe different programmes, but it may be modified in the light
of models identified in the literature.
For HIV care, the emerging models are giving rise to a variety of
terms, such as “decentralised,” “down referral,” and “delocalised.”
To help classify models and allow cross study comparisons, we
have developed a nomenclature (Table 2). This is not meant to
be definitive and may need to be modified as the models of care
develop, but provides a working framework for this review.
O B J E C T I V E S
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To evaluate retention, and quality of initiation andmaintenance of
HIV/AIDS care, in HIV treatment care models that decentralise
from hospitals to more basic levels of care.
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Randomised, non-randomised and controlled before-and-
after studies.
• Prospective and retrospective cohort studies with a
comparison between standard delivery of HIV treatment and
one where components of HIV treatment and care are delegated
to a lower level in the health care delivery system.
• Comparators need to be contemporary (delivered at the
same time), in the same country, and geographically adjacent
(such as adjacent districts within a province).
Types of participants
• HIV-infected patients at the point of initiating treatment.
• HIV-infected patients on treatment requiring maintenance
and follow up.
Types of interventions
Intervention
• Any form of care delivery that is decentralised out of the
hospital, for initiating treatment, continuing treatment, or both.
• Decentralised is defined as provision of treatment at a more
basic level in the health system than the control site (Table 1).
Control
• Care delivered at the usual site.
Types of outcome measures
Primary outcomes
• Retention: Any measure of comparative retention between
study populations at set time points after the intervention as
defined by the study authors.
• Death after being considered eligible for treatment, or
during treatment.
Secondary outcomes
• Time to initiation of antiretroviral treatment.
• Patients diagnosed with tuberculosis after entry into HIV
care.
• Virologic response to ART. This is the proportion of
participants that reach or maintain a pre-defined level of viral
load suppression, as defined by the study authors.
• Immunologic response to ART. This is the mean change in
the concentration of CD4+ lymphocytes from baseline, as
expressed in cells/µL.
• Occurrence of a new AIDS-defining illness. This is a newly
diagnosed WHO clinical stage 4 illness.
• Patient satisfaction with care, as defined by the study
authors. We will include qualitative analysis if available.
• Cost to the provider.
• Cost to the patient and family.
• Any negative impact on other programme and health care
delivery reported by the authors.
Search methods for identification of studies
See the Cochrane HIV/AIDS Group search strategy.
Electronic searches
In collaboration with the Trial Search coordinator of theCochrane
HIV Review Group, we will develop a comprehensive search strat-
egy to identify all relevant studies regardless of language or publi-
cation status (published, unpublished, in press, and in progress).
We will search from 1 January 1996 because triple-drug ART was
not used before this year. We will search the following electronic
databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL)
• MEDLINE
• EMBASE
• LILACS
• Web of Science
Key words will include MeSH terms and free-text terms relevant
to decentralisation, down referral, delivery of health care, health
services accessibility, and other relevant terms.
Searching other resources
Researchers and relevant organisations. We will contact indi-
vidual researchers working in the field and policymakers based
in inter-governmental organizations, including the Joint United
Nations Programme on HIV/AIDS (UNAIDS) and the World
Health Organization (WHO) to identify studies either completed
or ongoing.
Reference lists. We will check the reference lists of all studies
identified by the above methods and examine the bibliographies
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of any systematic reviews, meta-analyses, or current guidelines we
identify during the search process.
Ongoing studies. We will search the WHO International
Clinical Trials Registry Platform search portal for information on
unpublished and on-going trials.
Data collection and analysis
The methodology for data collection and analysis is based on the
guidance of Cochrane Handbook of Systematic Reviews of Inter-
ventions (Higgins 2008). Abstracts of all trials identified by elec-
tronic or bibliographic scanning will be examined by two authors
working independently. Where necessary, the full text will be ob-
tained to determine the eligibility of studies for inclusion.
Selection of studies
We will aim to remove duplicate references using a reference man-
agement software. Following this, a Cochrane research specialist
will do a broad review of results, excluding those that are clearly
irrelevant. Two authors will independently select potentially rele-
vant studies by scanning the titles, abstracts, and descriptor terms
of the remaining references and apply the inclusion criteria. Ir-
relevant reports will be discarded, and the full article or abstract
obtained for all potentially relevant or uncertain reports. The two
authors will independently apply the inclusion criteria. Studies
will be reviewed for relevance, based on study design, types of
participants, exposures and outcomes measures. A neutral third
party will adjudicate any disagreements that could not have been
resolved by discussion.
Data extraction and management
After initial search and article screening, two reviewers will inde-
pendently double-code and enter information from each selected
study onto standardised data extraction forms. Extracted informa-
tion will include:
• Study details: citation, start and end dates, location, study
design and details.
• Participant details: study population eligibility (inclusion
and exclusion) criteria, ages, population size, attrition rate,
details of HIV care and disease progression and any clinical,
immunologic or virologic staging, tuberculosis or laboratory
information.
• Interventions details: level of health service, cadre of health
worker and other forms of patient support, including diagnosis
of tuberculosis.
• Outcome details: retention in care, mortality, tuberculosis
case finding, AIDS-related progression of disease, virological and
immunological outcomes, patient satisfaction, cost of care.
The interventions will be carefully and systematically described,
to ensure that all of the interventions and co-interventions that
are reported are captured.
Assessment of risk of bias in included studies
Two review authors will independently assess the risk of bias within
the included studies against key criteria described below in ac-
cordance with methods recommended by the Cochrane Effec-
tive Practice and Organisation of Care (EPOC) Group and the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2008). The following judgments will be used: low risk of bias,
high risk of bias or unclear risk of bias (either due to lack of infor-
mation or uncertainty over the potential for bias). We will resolve
disagreements by consensus, or involve an arbitrator when neces-
sary.
Risk of bias for studies with a separate control group
Randomised controlled trials (RCTs);Non-randomised controlled
trials (NRCTs) and Controlled before-after (CBA) studies:
Nine standard criteria are suggested for all RCTs,NRCTs andCBA
studies from theEPOC.Further information canbe obtained from
the Cochrane Handbook section on risk of bias (Higgins 2008a).
1. Adequate generation of the allocation sequence
2. Adequate allocation concealment
3. Baseline outcome measurements were similar
4. Baseline characteristics were similar
5. Incomplete outcome data were adequately addressed
6. Knowledge of the allocated interventions was adequately
prevented during the study (where applicable)
7. The study was adequately protected against contamination
8. The study was free from selective outcome reporting
9. The study was free from other risks of bias
Cohort studies:
Wewill use theNewcastle-Ottawa Scale (Newcastle-Ottawa Scale)
to assess the quality and risk of bias in non-randomised studies.
Specifically, the scale uses a star system to judge three general areas:
selection of study groups, comparability of groups, and ascertain-
ment of outcomes (in the case of cohort studies). As a result, this
instrument can assess the quality of non-randomised studies so
that they can be used in a meta-analysis or systematic review.
Assessment of Quality of Evidence Across Studies
We will assess the quality of evidence across a body of evidence
(i.e., multiple studies with similar interventions and outcomes)
with the GRADE approach (Guyatt 2011), defining the quality
of evidence for each outcome as “the extent to which one can be
confident that an estimate of effect or association is close to the
quantity of specific interest” (Higgins 2008). The quality rating
across studies has four levels: high, moderate, low or very low.
Randomised controlled trials are initially categorised as provid-
ing high quality evidence, but the quality can be downgraded;
similarly, other types of controlled trials and observational stud-
ies are initially categorised as providing low quality evidence, but
the quality can be upgraded. Factors that decrease the quality of
evidence include limitations in design, indirectness of evidence,
unexplained heterogeneity or inconsistency of results, imprecision
of results or high probability of publication bias. Factors that can
increase the quality level of a body of evidence include a large
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magnitude of effect, if all plausible confounding would lead to an
underestimation of effect and if there is a dose-response gradient.
Measures of treatment effect
We will use Review Manager software (Review Manager 2011)
provided by the Cochrane Collaboration for statistical analysis
andGRADEpro software (GRADEpro 2008) to produceGRADE
Summary of Findings tables and GRADE Evidence Profiles. We
will summarise dichotomous outcomes for effect in terms of risk
ratio (RR) with their 95% confidence intervals. We will calculate
summary statistics using meta-analytic methods and present find-
ings in GRADE Summary of Findings tables and GRADE Evi-
dence Profiles for all outcomes of interest.
Dealing with missing data
Study authors will be contacted when missing data is an issue.
Assessment of heterogeneity
It is possible for some outcomes that meta-analysis may be con-
ducted. If it is, we will examine heterogeneity by using the χ2
statistic with a significance level of 0.10, and the I2 statistic. We
will interpret an I2 estimate greater than 50% as indicating mod-
erate or high levels of heterogeneity and will investigate its causes
(Deeks 2008).
Data synthesis
Data will be grouped by the tiers of service and care configurations
outlined in tables 1-2 (Table 1; Table 2). When interventions
and study populations are sufficiently similar across the different
studies, we will pool the data across studies and estimate summary
effect sizes using random-effects models. We will use the inverse
variance method for analysis of cluster randomised designs.The
inverse variance method assumes that the variance for each study
is inversely proportional to its importance, therefore more weight
is given to studies with less variance than studies with greater
variance.We will use the inverse variance method for analysis of
cluster randomised designs.
Wewill summarise the quality of evidence for the studies separately
for each outcome for which data is available in GRADE Summary
of Findings tables and GRADE evidence profiles (Guyatt 2011).
Subgroup analysis and investigation of heterogeneity
Data will be grouped by the tiers of service and care configurations
outlined in tables 1-2.
Sensitivity analysis
We will explore the pattern of results when non-randomised com-
parisons are excluded.
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A D D I T I O N A L T A B L E S
Table 1. Health service nomenclature in middle and low income countries
Tier Highest cadre Terms often used Facility and staff Equipment facilities
Community Individual with
maximum of few months
training; paid or unpaid
1a. Family led care Family member
1b. Village volunteer Trained volunteer; health
assistants
HIV tests, counselling, re-
plenish drugs
1c. Primary care clinic Nurse aide or community
health worker with a few
months training
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Table 1. Health service nomenclature in middle and low income countries (Continued)
Health centre Paramedic or nurse (2+
years training)
Health centres; district
hospitals
Purpose built with at least
one paramedic or nurse
with some health assis-
tants
HIV tests; antiretrovirals;
opportunistic infec-
tions medicines; point of
care laboratories
Hospital Doctor Health centres; district
hospitals
Purpose built with at least
one medical doctor with
nurses / paramedics and
assistants
CD4 count
Medicines
Not viral load
Advanced hospital Specialist doctor District hospital; referral
hospital
Purpose built with at least
2 specialist doctors with
nurses / paramedics and
assistants
Viral load and full investi-
gations
Table 2. Models of HIV care
Our term Initiation Follow up
Standard hospital model Hospital Hospital
Down referral (partial) Hospital Health centre
Down referral (full) Health centre Health centre
Delocalised Health centre (weekly clinics with hospital staff ) Health centre (weekly clinics with hospital staff )
Radical community Primary (tier 1c)
Health centre
Primary (tier 1c)
(monitor six monthly by health centre)
WH A T ’ S N E W
Date Event Description
8 June 2012 New citation required and major changes New authors taking forward this review.
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H I S T O R Y
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13 March 2009 Amended Converted to new review format.
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